Autologous transplantation for transformed non-hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 12, 2014, Pages 2072-2075

  Mei, Matthew ^a   Wondergem, Marielle J ^b   Palmer, Joycelynne M ^a   Shimoni, Avichai ^c   Hasenkamp, Justin ^d   Tsai, Ni Chun ^b   Simpson, Jennifer ^a   Nademanee, Auayporn ^a   Raubitschek, Andrew ^a   Forman, Stephen J ^a   Krishnan, Amrita Y ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SHEBA MEDICAL CENTER   (Israel)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Radioimmunotherapy; Z BEAM; Zevalin

Indexed keywords

CARMUSTINE; CYTARABINE; ETOPOSIDE; IBRITUMOMAB TIUXETAN; MELPHALAN; RITUXIMAB; YTTRIUM 90; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PODOPHYLLOTOXIN;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; AUTOGRAFT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOGRAFTS; CARMUSTINE; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; PODOPHYLLOTOXIN; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

EID: 84912122473     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.07.028     Document Type: Article

References (22)

1. Al-Tourah A.J., Gill K.K., Chhanabhai M., et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. JClin Oncol 2008, 26:5165-5169.
2. Berger F., Felman P., Thieblemont C., et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000, 95:1950-1956.
3. Montoto S., Davies A.J., Matthews J., et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. JClin Oncol 2007, 25:2426-2433.
4. Link B.K., Maurer M.J., Nowakowski G.S., et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. JClin Oncol 2013, 31:3272-3278.
5. Williams C.D., Harrison C.N., Lister T.A., et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. JClin Oncol 2001, 19:727-735.
6. Hamadani M., Benson D.M., Lin T.S., et al. High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Eur J Haematol 2008, 81:425-431.
7. Chen C.I., Crump M., Tsang R., et al. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. Br J Haematol 2001, 113:202-208.
8. Eide M.B., Lauritzsen G.F., Kvalheim G., et al. High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. Br J Haematol 2011, 152:600-610.
9. Ban-Hoefen M., Kelly J.L., Bernstein S.H., et al. High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era. Leuk Lymph 2012, 53:830-835.
10. Blaker Y.N., Eide M.B., Liestol K., et al. High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era. Leuk Lymph 2014, Published online ahead of print. http://dx.doi.org/10.3109/10428194.2013.871632.
11. Krishnan A., Nademanee A., Fung H.C., et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. JClin Oncol 2008, 26:90-95.
12. Shimoni A., Avivi I., Rowe J.M., et al. Arandomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer 2012, 118:4706-4714.
13. Bearman S.I., Appelbaum F.R., Buckner C.D., et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. JClin Oncol 1988, 6:1562-1568.
14. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. JClin Oncol 1999, 17:1244.
15. Guirguis H.R., Cheung M.C., Piliotis E., et al. Survival of patients with transformed lymphoma in the rituximab era. Ann Hematol 2014, 93:1007-1014.
16. Tam C.S., Herschtal A., Dickinson M., et al. Chemotherapy versus autologous stem-cell transplantation for the treatment of transformed follicular lymphoma in the rituximab era. JClin Oncol 2013, 31:3166-3167.
17. Wirk B., Fenske T.S., Hamadani M., et al. Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. Biol Blood Marrow Transplant 2014, 20:951-959.
18. Villa D., Crump M., Panzarella T., et al. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. JClin Oncol 2013, 31:1164-1171.
19. Ban-Hoefen M., Vanderplas A., Crosby-Thompson A.L., et al. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol 2013, 163:487-495.
20. Siddiqi T, Tsai N-C, Palmer J, etal. Effect of radioimmunotherapy-based conditioning for autologous stem cell transplantation on poor-risk molecular profiling in diffuse large B-cell lymphoma. ASCO Meeting Abstracts 2012;30:6547.
21. Briones J., Novelli S., Garcia-Marco J.A., et al. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica 2014, 99:505-510.
22. Vose J.M., Carter S., Burns L.J., et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol 2013, 31:1662-1668.